Cerebral Venous Thrombosis after Autologous Stem Cell Transplantation

Abstract

(4%). The median cell dose was 5.5 x 10 6 CD34+ cells/kg (range 2.86 to 12.3 x 10 6). No patient died within 100 days of transplant. The median follow up was 27 months (range 1.5 to 79.8). The median overall survival at 1 year, 3 years, and 5 years was 87%, 77%, and 77%. Relapse free survival at 1 year, 3 years, and 5 years was 78%, 68%, and 68%. In conclusion, bortezomib-based therapy followed by ASCT is well tolerated and can be performed with low TRM, resulting in durable OS and RFS.

Cortical Venous Thrombosis as an Initial Presentation of Multiple Myeloma: Report of a Case and Literature Review

“…In a case-control study, out of 594 CVT cases, 53 (8.9%) had a history of cancer, and only 2 cases had MM [10]. Four reported cases of CVT in association with MM till date have been summarised in Table 2 [11][12][13][14]. All were elderly females, median age-60 years (range, 52-83 years).…”